To test whether transcriptional interference based on MDM2LUTI occurs in a different cell type, we performed similar experiments in K562, a TP53−/− myeloid leukemia cell line that routinely shows robust CRISPRi-based repression (Gilbert et al. 2014). This evidence concerns the gene TP53 and myeloid leukemia.